<i>In vitro</i> cytotoxicity of SBT-1214 and paclitaxel against prostate CSC-enriched cell populations.

<p>Representative FACS analysis shows a dose-dependent increase in the ratios of CD133^high PPT2 (<b>A</b>) and PC3MM2 (<b>B</b>) cells 24 hours after treatment with SBT-1214 and Ptx. Longer treatment (for 72 hours) with SBT-1214 (10 nM-10 µM) induced up to 65% cell death in PPT2 cells (<b>C</b>) and up to 60% in PC3MM2 cells (<b>D</b>; lower line). In contrast, treatment with the same doses of Ptx did not suppress proliferation of the tumorigenic prostate cancer cells (<b>C, D</b>; upper line). Cells were incubated with indicated drug concentrations, and data was obtained with standard MMT assay based on three independent experiments with four repeats in each treatment group. Values are the means±SD.